[go: up one dir, main page]

NO20044282L - Selektiv malstyring til tumorvaskulatur ved anvendelse av antistoffmolekyler - Google Patents

Selektiv malstyring til tumorvaskulatur ved anvendelse av antistoffmolekyler

Info

Publication number
NO20044282L
NO20044282L NO20044282A NO20044282A NO20044282L NO 20044282 L NO20044282 L NO 20044282L NO 20044282 A NO20044282 A NO 20044282A NO 20044282 A NO20044282 A NO 20044282A NO 20044282 L NO20044282 L NO 20044282L
Authority
NO
Norway
Prior art keywords
antibody molecules
domain
employed
tumor vasculature
template control
Prior art date
Application number
NO20044282A
Other languages
English (en)
Norwegian (no)
Inventor
Christoph-Stephan Hilger
Barbara Carnemolla
Enrica Balza
Patrizia Castellani
Luciano Zardi
Laura Borsi
Matthias Friebe
Original Assignee
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen Spa filed Critical Philogen Spa
Publication of NO20044282L publication Critical patent/NO20044282L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Optics & Photonics (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
NO20044282A 2002-03-11 2004-10-08 Selektiv malstyring til tumorvaskulatur ved anvendelse av antistoffmolekyler NO20044282L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36304502P 2002-03-11 2002-03-11
PCT/IB2003/001458 WO2003076469A2 (fr) 2002-03-11 2003-03-11 Ciblage selectif d'un systeme vasculaire tumoral au moyen de molecules d'anticorps

Publications (1)

Publication Number Publication Date
NO20044282L true NO20044282L (no) 2004-10-08

Family

ID=27805258

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044282A NO20044282L (no) 2002-03-11 2004-10-08 Selektiv malstyring til tumorvaskulatur ved anvendelse av antistoffmolekyler

Country Status (22)

Country Link
US (1) US8491906B2 (fr)
EP (2) EP1483297B1 (fr)
JP (2) JP2005534283A (fr)
KR (1) KR100983385B1 (fr)
CN (1) CN100535013C (fr)
AT (1) ATE452912T1 (fr)
AU (1) AU2003219370B2 (fr)
BR (1) BRPI0308376B8 (fr)
CA (1) CA2478414C (fr)
CY (1) CY1109820T1 (fr)
DE (1) DE60330652D1 (fr)
DK (1) DK1483297T3 (fr)
ES (1) ES2337566T3 (fr)
IL (1) IL212702A0 (fr)
MX (1) MXPA04008810A (fr)
NO (1) NO20044282L (fr)
PL (1) PL374386A1 (fr)
PT (1) PT1483297E (fr)
RU (1) RU2347787C2 (fr)
SI (1) SI1483297T1 (fr)
WO (1) WO2003076469A2 (fr)
ZA (1) ZA200408107B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
EP1259548A1 (fr) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Anticorps specifique au domaine ed-b de la fibronectine, conjugues contenant cet anticorps, et utilisation pour la detection et le traitement de l'angiogenese
EP1514561A1 (fr) * 2003-09-10 2005-03-16 Philogen S.p.A. Ciblage de la vasculature tumorale avec l'utilisation de l'anticorps radio-marqué L19 contre le fibronectin ED-B
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
DE602004009169D1 (de) * 2004-07-22 2007-11-08 Bayer Schering Pharma Ag Verwendung von Cyanin-farbstoffen zur Diagnose von Krankheiten, welche mit Angiogenese assoziert sind
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
WO2007128557A1 (fr) * 2006-05-03 2007-11-15 Bayer Schering Pharma Aktiengesellschaft Combinaison d'un anticorps l19-sip anti domaine ed-b de la fibronectine et d'un anticorps anti-egfr
EP2085095B1 (fr) 2008-01-17 2012-03-07 Philogen S.p.A. Combinaison de protéine de fusion anticorps de fibronectine anti-EDb-IL-2, et molécule se liant aux lymphocytes B, progéniteurs de lymphocytes B et/ou leur contrepartie cancéreuse
KR100998569B1 (ko) * 2008-03-31 2010-12-07 한국원자력연구원 암 또는 전이암 진단 및 치료용 방사면역접합체，및 이를이용한 암 또는 전이암 억제제 개발
EP2116555A1 (fr) * 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Utilisation d'une molécule radiomarquée se liant spécifiquement à la fibronectine ED-B dans un procédé de traitement du lymphome Hodgkin
WO2014194784A1 (fr) * 2013-06-06 2014-12-11 合肥立方制药股份有限公司 Anticorps humains contre le domaine ed-b de la fibronectine et utilisations de ceux-ci
JP7039577B2 (ja) 2016-10-17 2022-03-22 ファイザー・インク 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
US11192943B2 (en) 2017-09-30 2021-12-07 Hefei Lifeon Pharmaceutical Co., Ltd. Protein binding to fibronectin B domain
TWI844524B (zh) 2018-02-09 2024-06-11 義大利商費洛根公司 靶向edb之il-12組合物
WO2020249757A1 (fr) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugués comprenant un dianticorps à chaîne unique et de l'interleukine-15 ou l'interleukine-15 et un domaine sushi du récepteur alpha de l'interleukine-15
US11872288B2 (en) 2020-05-22 2024-01-16 Philogen S.P.A. TNF-alpha immunoconjugate therapy for the treatment of brain tumors
WO2022061837A1 (fr) * 2020-09-27 2022-03-31 Jiangsu Cell Tech Medical Research Institute Co., Ltd. Car-t spécifique de l'extra-domaine b (edb) de la fibronectine pour le cancer
CA3242326A1 (fr) 2022-01-04 2023-07-13 Cipo Combinaison d'une immunocytokine comprenant l'il-12 et un inhibiteur de kinase
US20250262307A1 (en) 2022-08-01 2025-08-21 Philochem Ag Conjugates of psma-binding moieties with cytotoxic agents
WO2024052333A1 (fr) 2022-09-06 2024-03-14 Philochem Ag Ligands multivalents de protéine d'activation des fibroblastes pour applications d'administration ciblée
WO2025061801A1 (fr) 2023-09-19 2025-03-27 Philochem Ag Combinaison thérapeutique d'une protéine de fusion il2 ou il12 d'anticorps du domaine de la fibronectine anti-edb et d'un radioconjugué lutétium-177

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
FR2547061B1 (fr) * 1983-06-01 1985-07-05 Commissariat Energie Atomique Procede pour determiner l'activite volumique et estimer la masse de plutonium contenu dans des dechets et dispositif pour la mise en oeuvre de ce procede
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1994009817A1 (fr) 1992-11-04 1994-05-11 City Of Hope Nouvelle structure d'anticorps
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
CA2399866C (fr) 2000-02-24 2011-05-10 Philogen S.R.L. Compositions et procedes de traitement de l'angiogenese dans des lesions pathologiques
EP1259548A1 (fr) * 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Anticorps specifique au domaine ed-b de la fibronectine, conjugues contenant cet anticorps, et utilisation pour la detection et le traitement de l'angiogenese
EP1130099A1 (fr) 2000-02-25 2001-09-05 Crucell Holland B.V. Vitronectine activée comme marqueur d'angiogénèse détectée par des anticorps d'origine de phages
MXPA04006517A (es) * 2002-01-03 2005-03-31 Schering Ag Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
EP1514561A1 (fr) * 2003-09-10 2005-03-16 Philogen S.p.A. Ciblage de la vasculature tumorale avec l'utilisation de l'anticorps radio-marqué L19 contre le fibronectin ED-B

Also Published As

Publication number Publication date
IL212702A0 (en) 2011-07-31
DK1483297T3 (da) 2010-05-03
US8491906B2 (en) 2013-07-23
PL374386A1 (en) 2005-10-17
ES2337566T3 (es) 2010-04-27
BRPI0308376B1 (pt) 2020-03-10
JP2005534283A (ja) 2005-11-17
KR100983385B1 (ko) 2010-09-20
AU2003219370B2 (en) 2009-01-15
SI1483297T1 (sl) 2010-04-30
ATE452912T1 (de) 2010-01-15
EP1483297A2 (fr) 2004-12-08
JP2009268470A (ja) 2009-11-19
AU2003219370A1 (en) 2003-09-22
WO2003076469A9 (fr) 2005-09-29
RU2347787C2 (ru) 2009-02-27
PT1483297E (pt) 2010-03-29
EP1483297B1 (fr) 2009-12-23
CN100535013C (zh) 2009-09-02
ZA200408107B (en) 2005-12-28
DE60330652D1 (de) 2010-02-04
BRPI0308376A2 (pt) 2016-06-28
CY1109820T1 (el) 2014-09-10
WO2003076469A2 (fr) 2003-09-18
KR20040097163A (ko) 2004-11-17
CN1639195A (zh) 2005-07-13
CA2478414A1 (fr) 2003-09-18
CA2478414C (fr) 2012-11-13
RU2004130428A (ru) 2005-08-27
EP2174958A1 (fr) 2010-04-14
BRPI0308376B8 (pt) 2021-05-25
US20060057146A1 (en) 2006-03-16
MXPA04008810A (es) 2005-09-08
WO2003076469A3 (fr) 2003-11-27

Similar Documents

Publication Publication Date Title
IL212702A0 (en) Selective targeting of tumor vasculature using antibody molecules
EE200000802A (et) Fibronektiini ED-B regiooni vastased antikehad, neid sisaldavad konjugaadid ja nende kasutamine kasvajate ning angiogeneesiga seotud haiguste diagnoosimisel ja ravis
WO2004048525A3 (fr) Therapie de maladies ou troubles benins a l'aide d'anticorps anti-erbb2
CO5690537A2 (es) Formas solidas de anticuerpos anti-egfr
CY1108566T1 (el) Ανοσολογικος ελεγχος των επιπεδων του b-αμυλοειδους in vivo
EP1590434A4 (fr) Antigene associe au cancer du pancreas, anticorps correspondant et methodes de diagnostic et de traitement
CY1117031T1 (el) Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου
WO2003094862A3 (fr) Arnt synthase utilisee comme modulateur de l'angiogenese
DE69942148D1 (de) Gebrauch von bispezifischen antikörpern in diagnose und therapie
ATE390480T1 (de) Transplant-akzeptanz induzierende zellen monocytären ursprungs, sowie deren herstellung und verwendung
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
UA89759C2 (ru) Специфический связующий элемент, радиоактивно меченный 131и, который связывает человеческий ed-в фибронектина
EP1411962A4 (fr) Traitement par anticorps monoclonal du cancer du pancreas
ATE361096T1 (de) Antikörper zur modulierung der upa/upar interaktion und deren verwendungen
Vrathasha et al. Mechanisms of cellular internalization of quantum Dot® conjugated bone formation mimetic peptide CK2. 3
ITFI990094A1 (it) Metodo diagnostico per il riconoscimento di neoplasie umane attraverso la determinazione dell'isoforma ctn-c della tn-c,frammenti di
DE60125148D1 (de) Fctrx genannte proteine und dafür kodierende nuklein säure
Zhang et al. Programming an antibody-peptide sandwich procedure for selectivity and ultrasensitive detection of fibrin using double-stranded DNA (dsDNA) hemp string probe
DE602006004486D1 (de) Interleukin-13 als Marker für Herz-Kreislauf-Erkrankungen
FONTECHA CUENCA Production and Molecular Design of Recombinant Proteins for Nanoparticle Functionalization and for the Protein Corona Modulation
DE60333820D1 (de) Konjugate mit einem für die ed-b-domäne von fibronectin spezifischen antikörper, und deren verwendung zum nachweis und zur behandlung von tumoren
van der Wal Hairy Tongue
WO2004055211A3 (fr) Compositions et methodes pour la detection et le traitement de pathologies neurodegénératives
BG105030A (en) Antibodies against ed-b domain of fibronectin, conjugates containing them, and their application for diagnostics and treatment of tumours and morbid conditions related to angiogenesis
ATE409221T1 (de) Acylglycerin-acyltransferase-ähnliches protein mgat-x1 und verwendungen davon

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application